Status:
UNKNOWN
Lanreotide Levels in Acromegaly
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Brief Summary
Recently lanreotide (a somatostatin analog) has come into the US marketplace as a commercially available medication approved by the FDA for the treatment of acromegaly. Blood levels in patients gettin...
Eligibility Criteria
Inclusion
- 18 years or older
- Receiving lanreotide depot for treatment of acromegaly
Exclusion
- Unwilling to provide consent
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00916916
Last Update
June 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048